Why the study?
Are preventive cardiovascular interventions cost-effective for reducing cardiovascular disease occurrence in adults in low and middle-income countries?
Are preventive cardiovascular interventions cost-effective for reducing cardiovascular disease occurrence in adults in low and middle-income countries?
A wide range of preventive cardiovascular interventions, both population-based and pharmacological, are cost-effective in low and middle-income countries.
No takes yet. Share an insight, caveat, or question.
Supports scaling preventive CV interventions in LMICs; extends cost-effectiveness evidence to resource-limited settings.
Shroufi et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: